间歇性内分泌药物治疗晚期前列腺癌的疗效观察

目的间歇性内分泌药物治疗(IHT)晚期前列腺癌的疗效及安全性。方法回顾分析IHT晚期前列腺癌患者36例,其中黄体生成素释放激素类似物(LHRHa)联合应用比卡鲁胺28例(A组);单纯睾丸切除术8例(B组)。分析比较两组患者在临床表现,血清PSA值,生存率,药物不良反应等方面的差异。结果 A组患者症状缓解率为80.8%(18/28),B组患者症状缓解率为70.6(3/8);A组PSA值由治疗前的143.3(18.7～996.8)ng/mL下降至15.8(0.02～28.9)ng/mL,B组由治疗前的142.3(27.1～988.0)ng/mL下降至27.6(6.0～62.1)ng/mL;A组生化复发率为34.6%(9/28),B组为58.3%(5～8)个月;A组生化复发时间为22(6～65个月A组为10(6～56)个月;A组病死率为25%(7/28),B组病死率为75%(6/8)。服用比卡鲁胺持续用药患者85.5%(22/28)服药期间无明显药物不良反应。结论 IHT应用比卡鲁胺治疗前列腺癌安全、有效。

Efficacy and Safety of Intermittent Hormonal therapy(IHT) in Advanced Prostate Cancer Patients

Objective To compare the efficacy, safety and side-effects of IHT of advanced prostate cancer patients. Methods Thirty-six advanced prostate cancer patients were treated with hormonal therapy.The patients were divided into 2 groups, of 28 patients（groupA） used IHT; 8 patients （groupB） were treated with castration only. The difference of clinical symptoms, serum PSA, survival rate, and side-effects of 2 groups were compared. Results The relief rates of group A 80.8%（18/28）, groupB 70.6%（3/8）. The mean serum PSA of group A decreased from 144.3（18.7-996.8）ng/mL to 15.8（0.02-28.9）ng/ml, group B decreased from 142.3（27.1-988.0）ng/mL to 27.6（6.0-62.1）ng/mL. The mean chemical recurrence rates of group A 34.6%（9/28）, group B 58.3%（5/8）. The mean chemical recurrence time of group A 22（6-65） month, group B 10（6-56） month. The mortality rates of group A 25%（7/28）, group B 75%（6/8）. 85.5%（22/28） of group A were treated with IHT continuously, the side-effects rate of group A was low. Conelusion Bicalutamide is effective and safe as IHT for prostate cancer patients.